NanoVibronix, Inc. (NAOV): Price and Financial Metrics
NAOV Price/Volume Stats
Current price | $0.88 | 52-week high | $4.34 |
Prev. close | $0.90 | 52-week low | $0.73 |
Day low | $0.88 | Volume | 421 |
Day high | $0.88 | Avg. volume | 111,917 |
50-day MA | $0.99 | Dividend yield | N/A |
200-day MA | $1.83 | Market Cap | 1.80M |
NAOV Stock Price Chart Interactive Chart >
NAOV Stock Summary
- NAOV has a higher market value than just 0.97% of US stocks; more precisely, its current market capitalization is $2,189,550.
- For NAOV, its debt to operating expenses ratio is greater than that reported by just 3.97% of US equities we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NAOV comes in at -288.37% -- higher than that of just 1.54% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to NANOVIBRONIX INC, a group of peers worth examining would be CPHI, TCMD, AQB, AOUT, and ALPP.
- NAOV's SEC filings can be seen here. And to visit NANOVIBRONIX INC's official web site, go to www.nanovibronix.com.
NAOV Valuation Summary
- NAOV's EV/EBIT ratio is 0.3; this is 97.95% lower than that of the median Healthcare stock.
- Over the past 105 months, NAOV's price/sales ratio has gone down 42.4.
Below are key valuation metrics over time for NAOV.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
NAOV | 2023-12-29 | 2.4 | 0.5 | -0.5 | 0.3 |
NAOV | 2023-12-28 | 2.5 | 0.5 | -0.5 | 0.3 |
NAOV | 2023-12-27 | 2.3 | 0.5 | -0.5 | 0.3 |
NAOV | 2023-12-26 | 2.3 | 0.5 | -0.5 | 0.3 |
NAOV | 2023-12-22 | 2.1 | 0.4 | -0.4 | 0.4 |
NAOV | 2023-12-21 | 2.1 | 0.4 | -0.4 | 0.4 |
NAOV Growth Metrics
- Its 2 year cash and equivalents growth rate is now at 1252.14%.
- The 3 year net cashflow from operations growth rate now stands at -42.38%.
- Its 3 year price growth rate is now at -78.91%.
The table below shows NAOV's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 1.629 | -6.567 | -5.863 |
2022-06-30 | 2.031 | -5.237 | -11.583 |
2022-03-31 | 1.864 | -5.154 | -10.497 |
2021-12-31 | 1.695 | -4.367 | -14.282 |
2021-09-30 | 1.01 | -4.822 | -12.813 |
2021-06-30 | 0.661 | -4.883 | -7.06 |
NAOV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NAOV has a Quality Grade of D, ranking ahead of 5.54% of graded US stocks.
- NAOV's asset turnover comes in at 0.095 -- ranking 154th of 186 Medical Equipment stocks.
- NUWE, SIEN, and ATRS are the stocks whose asset turnover ratios are most correlated with NAOV.
The table below shows NAOV's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.095 | 0.620 | 20.273 |
2021-03-31 | 0.112 | 0.392 | 13.158 |
2020-12-31 | 0.172 | 0.343 | 8.655 |
2020-09-30 | 0.300 | 0.261 | -32.726 |
2020-06-30 | 0.316 | 0.193 | -30.341 |
2020-06-30 | 0.316 | 0.193 | -30.341 |
NanoVibronix, Inc. (NAOV) Company Bio
NanoVibronix, Inc. operates as a medical device company. The Company focuses on non-invasive biological response-activating devices that target wound healing and pain therapy. NanoVibronix develops medical devices based on its proprietary therapeutic ultrasound technology.
Latest NAOV News From Around the Web
Below are the latest news stories about NANOVIBRONIX INC that investors may wish to consider to help them evaluate NAOV as an investment opportunity.
NanoVibronix Featured in Your Bladder Health MagazineELMSFORD, N.Y., December 06, 2023--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield is featured in Issue 103 of Your Bladder Health Magazine in an article titled ‘UroShield Prevention is better than cure.’ The article highlights the effectiveness of using UroShield in the prevention of catheter associated urinary tract infe |
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution OpportunityELMSFORD, N.Y., December 04, 2023--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the "LOI") with APOGEPHA Arzneimittel GmbH ("APOGEPHA") in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix’s premiere UroShield product in Germany and other European |
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of MichiganELMSFORD, N.Y., November 28, 2023--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial ("RCT") study of UroShield. |
NanoVibronix Regains Nasdaq ComplianceELMSFORD, N.Y., November 21, 2023--NanoVibronix, Inc., (NASDAQ: NAOV) (the "Company"), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that on November 20, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the minimum stockholders’ eq |
NanoVibronix Issues Letter to ShareholdersELMSFORD, N.Y., November 14, 2023--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the third quarter 2023 and recent business developments. |
NAOV Price Returns
1-mo | -25.42% |
3-mo | -13.89% |
6-mo | -65.08% |
1-year | -74.86% |
3-year | -96.04% |
5-year | -98.89% |
YTD | -23.48% |
2023 | -77.18% |
2022 | -75.77% |
2021 | 36.11% |
2020 | -73.19% |
2019 | -21.27% |
Continue Researching NAOV
Here are a few links from around the web to help you further your research on NanoVibronix Inc's stock as an investment opportunity:NanoVibronix Inc (NAOV) Stock Price | Nasdaq
NanoVibronix Inc (NAOV) Stock Quote, History and News - Yahoo Finance
NanoVibronix Inc (NAOV) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...